PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
149.60%
Cash & equivalents yoy growth below half of CRVO's 12121.13%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
149.60%
Below half of CRVO's 12121.13%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
133.42%
Below half of CRVO's 999.28%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
835.01%
Below half CRVO's -31.02%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1079.37%
≥ 1.5x CRVO's 5.56%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
135.47%
1.25-1.5x CRVO's 106.18%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
69.91%
Less than half of CRVO's -84.26%. David Dodd sees a more disciplined AP approach or lower volume.
-41.82%
50-75% of CRVO's -68.79%. Bruce Berkowitz notes the firm is less reliant on near-term borrowing than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-49.13%
50-75% of CRVO's -67.38%. Bruce Berkowitz notes a more controlled liability line.
-44.50%
50-75% of CRVO's -61.37%. Bruce Berkowitz notes the firm keeps current liabilities growth relatively low.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-44.50%
1.25-1.5x CRVO's -35.14%. Martin Whitman is wary of bigger liability expansions.
7.98%
Less than half of CRVO's 111.78%. David Dodd sees fewer share issuances vs. competitor.
4.22%
Below half CRVO's -6.90%. Michael Burry suspects major net losses or high dividends vs. competitor.
-271.57%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
132.15%
Below half CRVO's 270.84%. Michael Burry sees potential underperformance in building shareholder capital.
135.47%
1.25-1.5x CRVO's 106.18%. Bruce Berkowitz checks if expansions are well-justified by ROI.
No Data
No Data available this quarter, please select a different quarter.
-41.82%
50-75% of CRVO's -68.79%. Bruce Berkowitz sees relatively smaller yoy debt additions.
-152.72%
Less than half of CRVO's -1067.72%. David Dodd sees better deleveraging or stronger cash buildup than competitor.